Brief: Avadel Pharmaceuticals Announces Strong Lumryz Launch Performance

Avadel Pharmaceuticals

08/01/2024 13:22

Jan 8 (Reuters) - Avadel Pharmaceuticals PLC  AVDL.O :
    * AVADEL PHARMACEUTICALS ANNOUNCES STRONG LUMRYZ LAUNCH
PERFORMANCE AND PROVIDES PRELIMINARY FOURTH QUARTER AND FULL
YEAR 2023 FINANCIAL HIGHLIGHTS
    * AVADEL PHARMACEUTICALS: APPROXIMATELY $19 MILLION AND $28
MILLION OF NET REVENUE FROM SALES OF LUMRYZ™ ESTIMATED FOR Q4
AND FULL YEAR 2023
    * AVADEL PHARMACEUTICALS PLC: SUPPLEMENTAL NEW DRUG
APPLICATION
(SNDA) FOR LUMRYZ IN PEDIATRIC NARCOLEPSY POPULATION ACCEPTED BY
FDA
    * AVADEL PHARMACEUTICALS PLC:  APPROVAL FOR LUMRYZ EXPECTED
IN
SEPTEMBER 2024

Source text for Eikon:  ID:nGNX9KFlpX 
Further company coverage:  AVDL.O 

 ((Reuters.Briefs@thomsonreuters.com;))